BioXcel Therapeutics Inc.

1.63
-0.19 (-10.44%)
At close: Apr 04, 2025, 3:59 PM
1.49
-8.31%
Pre-market: Apr 07, 2025, 05:55 AM EDT

Company Description

BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology.

The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices.

Its commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

The company also continues to conduct clinical trials evaluating BXCL501 for the treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia.

In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally administered, systemic innate immunity activator for the treatment of aggressive forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors.

The company was incorporated in 2017 and is headquartered in New Haven, Connecticut.

BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc. logo
Country United States
IPO Date Mar 8, 2018
Industry Biotechnology
Sector Healthcare
Employees 37
CEO Dr. Vimal D. Mehta Ph.D.

Contact Details

Address:
555 Long Wharf Drive
New Haven, Connecticut
United States
Website https://www.bioxceltherapeutics.com

Stock Details

Ticker Symbol BTAI
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001720893
CUSIP Number 09075P105
ISIN Number US09075P1057
Employer ID 82-1386754
SIC Code 2834

Key Executives

Name Position
Dr. Vimal D. Mehta Ph.D. Founder, Chief Executive Officer, President, & Director

Latest SEC Filings

Date Type Title
Apr 04, 2025 S-8 Filing
Apr 03, 2025 8-K Current Report
Apr 03, 2025 424B5 Filing
Apr 01, 2025 4 Filing
Apr 01, 2025 4 Filing
Apr 01, 2025 4 Filing
Apr 01, 2025 4 Filing
Apr 01, 2025 4 Filing
Apr 01, 2025 4 Filing
Apr 01, 2025 4 Filing